mpp

MPP+ iodide, the metabolite of a neurotoxin MPTP, causes symptom of Parkinson's disease (PD) in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ induces dopamine transporter (DAT) externalization in dopaminergic (DA)

MPP dihydrochloride is a highly selective antagonist of estrogen receptor alpha (ERα).

MPP hydrochloride is a selective estrogen receptor (ERR) modulator.

MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.

MPTP hydrochloride is a precursor of MPP+, a dopamine neurotoxin with blood-brain barrier permeability. MPTP hydrochloride is toxic to dopaminergic neurons, which can lead to Parkinson's disease, and is widely used in the construction of animal models of Parkinson's disease.

Vanillyl Alcohol (3-Methoxy-4-hydroxybenzyl alcohol) possesses anti-angiogenic, anticonvulsive, anti-inflammatory, anti-oxidant, neuroprotective, and anti-nociceptive activities. Vanillyl alcohol can effectively inhibit the cytotoxicity and improved cell viability in 1-methyl-4-phenylpyridinium (MPP+)-induced MN9D dopaminergic cells, it also can attenuate the elevation of reactive oxygen species (ROS) levels, decrease in the Bax/Bcl-2 ratio and poly (ADP-ribose) polymerase proteolysis.

3-MPPI was a high-affinity nonselective α1-antagonist.

MPPG is a selective L-AP4-sensitive receptor antagonist (kD=9.2 μM).

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.

R-IMPP is an inhibitor of PCSK9 translation. R-IMPP stimulates uptake of LDL-C in hepatoma cells by increasing LDL-R levels, without altering levels of secreted transferrin.

AMPPD (Lumi-Phos Plus) is a 1,2-dioxo-cyclohexane derivative and a substrate for hypersensitive alkaline phosphatase.

High affinity κ agonist

p-MPPI hydrochloride is a selective antagonist of 5-HT1A receptor, and has antidepressant and anxiolytic-like effects.

Mppf F-18, which has been used as a radioactive ligand for positron emission tomography, is a compound that binds to the serotonin-1A receptor.

glutamate carboxypeptidase II (GCP II) inhibitor

p-MPPF dihydrochloride is a selective 5-ht1a serotonin receptor antagonist

BemPPOX is a potent inhibitor of DGL.

TMPPAA is an allosteric agonist of 5-HT3 receptor.

Cyclocurcumin, a curcumin derivative, exhibits anticancer, anti-inflammatory, and immune-modulating abilities and is a potential compound for the treatment of rheumatoid arthritis as predicted by the MM-PBSA method. It may have a therapeutic potential as

Licopyranocoumarin could as a potent neuroprotective drug via markedly blocked MPP+-induced neuronal PC12D cell death and disappearance of mitochondrial membrane potential, which were mediated by JNK.

CBR-470-1 is a potent inhibitor of glycolytic phosphoglycerate kinase 1 (PGK1) that activates NRF2 by increasing methylglyoxal levels. CBR-470-1 is a non-covalent Nrf2 activator with neuroprotective activity that protects SH-SY5Y neuronal cells from MPP+-induced cytotoxicity by activating the Keap1-Nrf2 cascade. cytotoxicity induced by MPP+.

LZWL02003, an anti-neuroinflammatory agent, demonstrates a protective effect on MPP+-induced neuronal damage and reduces ROS expression. Additionally, it enhances cognition, memory, learning, and athleticism in Rotenone-induced Parkinson's disease (PD) rat models, suggesting its potential for neurodegenerative disease research [1].

SNJ-1945 is a calpain inhibitor with more favorable retinal penetration, high oral bioavailability, and long half-life. SNJ1945 rescued defective function in lissencephaly. SNJ-1945 protects SH-SY5Y cells against MPP(+) and rotenone. SNJ-1945 reduces murine retinal cell death in vitro and in vivo. SNJ-1945 has good aqueous solubility, can prevents the heart from KCl arrest-reperfusion injury associated with the impairment of total Ca(2+) handling by inhibiting the proteolysis of alpha-fodrin as a cardioplegia.

Smilagenin is an orally active inducer of nonpeptide neurotrophic factor. It also prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons, and by MPTP in a mouse model of Parkinson's disease.

SU-4312, also known as DMBI, is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). SU4312 (SU 4312) unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS.

Paeoniflorin (Peoniflorin) is a herbal constituent extracted from the root of Paeonia albiflora Pall.

Galgravin has anti-inflammatory, and neuroprotective effects, it can promote neuronal survival and neurite outgrowth, protect hippocampal neurons against amyloid beta peptide (Abeta25-35)-induced cytotoxicity, and protect against neuronal death from 1-met